Mequin (Mefloquine) is a commonly used antimalarial agent that is applied across two relevant therapeutic contexts: helping manage existing infections and providing appropriate prevention. The medication is utilized for both treatment and prophylaxis.

Key therapeutic domains include the management of acute symptomatic episodes of malaria and providing chemoprophylaxis for individuals traveling to endemic areas. It is applied in clinical settings that involve infections associated with the parasitic species P. falciparum, including those that are chloroquine-resistant, and P. vivax.

Treatment and Prevention Contexts

Mequin is commonly used to help manage acute symptomatic episodes, supporting relief for symptoms related to systemic imbalance, such as recurring high fever and severe chills. In a preventative role, the medication is relevant for antimalarial chemoprophylaxis in high-risk regions. The main patient-oriented benefit is contributing to improved comfort and functional stability by supporting prevention of the disruptive disease, and is relevant for strains associated with increased challenge.

Quick Fact: Supportive Management for Systemic Imbalance Mequin is commonly used to help manage symptom clusters that may become intense or disruptive, and assists with easing the acute systemic febrile illness associated with parasitic infection.

Official Population Eligibility for Mequin

Mequin (mefloquine) eligibility is strictly defined by regulatory authorities, with most prohibitions centered on neuropsychiatric and hepatic health.

Classification	Population/Condition	Restriction Basis (Official Label)
Contraindicated	Active depression, psychosis, schizophrenia, or other major psychiatric disorders (Prophylaxis use only)	Established risk of serious neuropsychiatric events [2.4, 2.7]
Contraindicated	History of convulsions or seizures; Hypersensitivity to mefloquine, quinine, or quinidine	Risk of increased convulsive activity; known allergic reaction [2.4, 3.4]
Contraindicated	Severe impairment of liver function (Prophylaxis use only)	Drug is primarily metabolized by the liver [2.4, 2.7]
Conditional Use	Epilepsy	Contraindicated for prophylaxis; restricted to curative treatment only if compelling medical reasons exist [2.4, 3.4]
Conditional Use	Non-severe liver disease or cardiac conduction abnormalities	Use with caution; may require monitoring or clinical assessment [2.4, 2.7]

Age and Reproductive Status:

Mequin is officially approved for use in adults and children, with pediatric dosage extrapolated from the adult dose [3.4]. Safety and efficacy have not been established for infants under six months of age [2.5].

For pregnant women, use for malaria treatment is generally considered appropriate, particularly during the second and third trimesters, as authorized by major guidelines [3.1, 3.2]. Use during lactation requires consultation, as the drug passes into breast milk [3.4].

Interactions with other medicines and products

The official regulatory interaction profile for Mequin (Mefloquine) is defined by pharmacokinetic and pharmacodynamic relationships with other medicinal products and mandatory administration constraints.

Interaction Classifications

Interaction Type	Interacting Substance(s)	Official Constraint/Outcome
Formal Contraindication	Halofantrine, Ketoconazole	Prohibited for co-administration or within 15 weeks of Mequin due to documented risk of potentially fatal QTc prolongation.
Pharmacodynamic Risk	Quinine, Quinidine, Chloroquine	Concomitant use documented to produce electrocardiographic abnormalities and increase the risk of convulsions.

Exposure and Administration Rules

Certain substances affect Mequin's systemic exposure. The strong CYP3A4 inhibitor Ketoconazole is documented to increase Mequin’s plasma concentrations, while the inducer Rifampin is documented to decrease them. Furthermore, Mequin may lower the plasma levels of co-administered anticonvulsant medicines, which can officially reduce seizure control.

Mandatory timing rules govern administration with live vaccines and other antimalarials. Vaccination with Oral Live Typhoid Vaccines must be completed at least three days before the first dose of Mequin. If Quinine or Chloroquine is used for the initial treatment of severe malaria, Mequin administration must be delayed at least 12 hours after the last dose.

Targeted Inhibition of Parasite Protein Synthesis

Mefloquine acts as an inhibitor by binding to the 80S ribosome within the actively multiplying asexual blood stages of the Plasmodium parasite. This molecular action halts the translation of proteins essential for parasite growth and replication, leading directly to cellular stress and death of the blood-stage parasite (blood schizonticidal effect).

Off-Target Modulation of Human CNS Pathways

In addition to its anti-parasitic action, the molecule engages in off-target modulation by acting as a partial agonist at human 5-HT2A receptors and inhibiting connexin hemi-channels in the central nervous system. This alters the balance of neurotransmission and neuronal excitability, resulting in modulation of CNS function.

Mechanistic Constraints and Specificity

The mechanism is constrained by the life-stage specificity of the drug, making it ineffective against the dormant liver stages (hypnozoites) of certain Plasmodium species. Furthermore, PfMDR1 transporter-mediated efflux is a resistance mechanism that actively limits the effective concentration of the drug at its ribosomal target.

Mequin is an antimalarial agent provided solely in an oral tablet formulation, containing 250 mg of mefloquine hydrochloride. The administration protocol requires the tablet to be taken with a meal and a substantial amount of fluid, such as 240 mL (8 ounces) of water, to ensure the medication is not taken on an empty stomach. For patients who cannot swallow the tablet whole, it may be crushed and suspended in a small quantity of liquid, such as water or milk.

Dosing Regimens and Schedule

Dosing is strictly dependent on the usage context. For acute malaria treatment, the required total dose is 1250 mg (five tablets), which may be given as a single event or divided into 750 mg followed by 500 mg six to twelve hours later. For malaria prophylaxis, the standard dose is 250 mg (one tablet) taken once weekly on the same day each week. Pediatric dosing for both treatment and prevention is defined based on the patient's body weight (kilograms), with the resulting dose not to exceed the established adult dosage.

Course Duration and Procedural Conditions

The prophylaxis regimen must begin 1 to 2 weeks before entry into the endemic area, continue for the duration of the stay, and be maintained for a further four consecutive weeks after departure. The maximum recommended period for continuous prophylactic use is 12 months. If vomiting occurs less than 30 minutes after a dose, a full repeat dose should be administered; if it occurs 30 to 60 minutes, an additional half-dose should be administered.

Research evidence / Overview of Studies for Mequin

Evidence for Use in Acute Malaria Treatment

Research exploring how Mequin is studied for active malaria was evaluated in Randomized Controlled Trials (RCTs) and pooled analyses in adults and children with uncomplicated infections, including those caused by drug-resistant strains of Plasmodium falciparum and P. vivax. Studies explored Mequin’s use in patients during periods of heightened symptom activity, particularly outcomes related to systemic or functional imbalance.

Researchers primarily focused on measurements like the Parasite Clearance Rate and the Fever Clearance Time, which relates to the time required for symptoms to subside. The research also monitored the frequency of infection recurrence after the specified follow-up period, often extending to 42 days, to assess outcomes related to disease return. The evaluation in acute settings frequently includes Mequin when it was studied as part of a combination regimen.

---

Evidence for Use in Malaria Prevention (Chemoprophylaxis)

Research into Mequin’s use for malaria prevention was studied for non-immune individuals traveling to or residing in endemic areas. This evidence comes from comparative trials and systematic reviews that examined Mequin alongside placebo or other preventive medications. In comparative trials, studies monitored the frequency of acquiring malaria in groups receiving Mequin versus a control group. When compared against other studied preventive medications, research described patterns in the measured incidence of malaria among the options.

---

Consistency and What Remains Uncertain

Evidence is limited for Mequin’s effect against less common malaria parasites, P. ovale and P. malariae. The certainty remains low for outcomes related to these species, and the results apply only to the populations studied in the existing trials. Studies observed that Mequin was not associated with action against the liver-stage (hepatic) parasites in P. vivax malaria. This means that recurrence may still occur, and research describes that outcomes related to this parasitic stage often require separate study. Long-term effects are not fully established because follow-up durations were limited in many studies.

Key Studies & References

1. Recommendations for the Prevention of Malaria Among Travelers - CDC (Initial evidence and regimen changes)

Common questions about Mequin (FAQ)

Q: How quickly should I expect Mequin to start working?

According to official product information, after taking a single dose, the drug's levels in the blood typically reach their maximum point within 6 to 24 hours. When used for weekly prevention of malaria, it generally takes about 7 to 10 weeks of regular dosing for the drug to reach steady-state concentrations in the body.

Q: How long does the effect of one dose of Mequin usually last?

Mequin has a long elimination half-life, which describes the time it takes for half of the drug to be removed from the body. In healthy adults, this period typically averages about three weeks, ranging from two to four weeks. This long duration is noted in regulatory information regarding weekly dosing for prevention.

Q: Is Mequin safe to use while breastfeeding?

Official information indicates that only very small amounts of Mequin are known to pass into breast milk. The amount is described in official sources as not being sufficient to cause harm to the infant, nor is it sufficient to provide the infant with protection against malaria. Regulatory guidelines state that consultation with a healthcare provider is required regarding use of the drug during lactation.

Q: What happens if I miss a dose of Mequin?

If a dose is missed, regulatory dosing information describes the protocol as taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the guidance states that the missed dose should be skipped to return to the regular schedule and avoid taking a double dose.

Q: Does Mequin interact with alcohol?

Regulatory documents suggest that combining Mequin with alcohol may increase the risk of central nervous system (CNS) side effects. These CNS effects can include issues such as dizziness or loss of balance, due to the way both substances affect the nervous system.

Q: Can Mequin be crushed or split?

Official administration instructions state that for individuals unable to swallow the tablet whole, the tablet can be crushed and suspended in a small amount of liquid or food. This method is described as being permitted for use when the full dose cannot be swallowed whole.

Q: Are there specific times of day that Mequin is typically recommended to be taken?

For weekly malaria prevention, Mequin must be taken on the same day each week. The official instructions recommend taking the tablet preferably after the main meal of the day.

Q: Do I need to change my diet while taking Mequin?

Official administration guidelines state that the drug should be taken with a meal and a substantial amount of fluid, such as 8 ounces of water. This is noted in the labeling to help the body absorb the medicine properly, but no other specific dietary modifications are generally mandated.

Q: I heard Mequin is similar to [Drug X]. What is the key difference in purpose?

Mequin is officially classified as a blood schizonticide, defined by its specific action against the asexual blood stages of Plasmodium parasites. This means its primary function, according to regulatory documents, is to halt protein production in the parasite, causing cell death, and it is used for both the treatment and prevention of malaria.

Q: Does Mequin treat the cause of the problem or just the symptoms?

Official information describes Mequin's primary function as a blood schizonticide, which works by directly causing the death of the actively multiplying blood-stage Plasmodium parasite, addressing the cause of the infection. Research also monitors symptom-related outcomes like Fever Clearance Time.

Q: Can Mequin cause long-term side effects?

The FDA Boxed Warning notes that serious adverse reactions involving the nervous and psychiatric systems have been reported to persist for months to years after the drug is discontinued. In some documented cases, these effects have been noted to be permanent.

Q: How long has Mequin been available on the market?

Based on official records from U.S. regulatory bodies, the active ingredient in Mequin, mefloquine, was approved for use in the United States in 1989. This date of approval means the drug is generally considered a long-established medication in its therapeutic class.

Q: Is Mequin a controlled substance?

Mequin is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major government bodies.

Q: What is the difference between the generic and brand name versions of Mequin?

The active ingredient in both the generic and brand-name versions is Mefloquine hydrochloride. Regulatory standards require generic formulations to meet the same quality, strength, and effectiveness requirements as the brand-name product.

Q: Does Mequin require a prescription from a doctor?

Yes, Mequin is officially designated as a prescription-only medication in countries that regulate its use, meaning it requires authorization from a licensed healthcare provider.

Q: Is it possible for Mequin to stop working over time?

Regulatory documents describe the development of drug resistance in Plasmodium parasites in certain geographic areas. This involves specific resistance mechanisms that can limit the drug's effectiveness against those particular parasite strains.

Q: Does Mequin affect lab tests, like blood or urine tests?

Yes, official labeling recommends periodic evaluation, including liver function tests, when the drug is administered for a prolonged period.

Q: If I have a kidney problem, is Mequin still an option?

Official labeling states that Mequin is mainly eliminated by the liver, not the kidneys. Because only a small amount of the drug is removed by the kidneys, no special dosage adjustments for chemoprophylaxis are needed for patients undergoing dialysis.

Q: How is Mequin absorbed and removed from the body?

The drug's absorption into the bloodstream is enhanced when it is taken with food. It is primarily metabolized (broken down) by the liver, and the majority of the drug is eliminated from the body via the bile and feces.

Q: Why are people often confused about whether Mequin is for [Condition A] or [Condition B]?

The official purpose is the prevention and treatment of malaria, particularly P. falciparum and P. vivax. Due to its spectrum of activity and sometimes complex administration protocols, clarification is often necessary regarding its precise role compared to other medications used for anti-parasitic treatment.

Q: Are there specific patient groups where Mequin is studied more than others?

Research has primarily focused on specific groups to gather evidence. These include non-immune individuals traveling to endemic areas, as well as trials involving adults and children with uncomplicated malaria.

Q: What kind of studies (e.g., Phase 3 trials) were done for Mequin?

The evidence supporting the use of Mequin comes from rigorous types of studies, such as Randomized Controlled Trials (RCTs) and various clinical trials, including Phase II studies, which were conducted to evaluate its effectiveness.

Q: Are there any common reasons why a doctor might discontinue Mequin?

Official labeling describes conditions where immediate discontinuation of the medication is necessary if the patient develops specific symptoms. These symptoms include psychiatric changes, such as anxiety, depression, restlessness, or confusion, or neurological symptoms, such as dizziness or loss of balance.

Q: Is Mequin considered an 'old' or 'new' drug?

Based on official records, the active ingredient in Mequin, mefloquine, was approved for use in the United States in 1989. This date of approval means the drug is generally considered a long-established medication in its therapeutic class.

How to Store and Dispose of Mequin

Mequin (mefloquine hydrochloride) must be stored according to regulatory requirements to ensure product stability and public safety.

Storage Conditions

Requirement	Specific Condition
Temperature	Store below 30 C (86 F). The recommended range is 15 C to 30 C.
Protection	Protect from moisture.
Packaging	Store in the original package and keep tablets in their blister until use.
Child Safety	Must be kept out of the reach of children and stored in a locked-up location.

Disposal Instructions

Unused or expired Mequin must be disposed of as controlled pharmaceutical waste, not with household garbage. Disposal must strictly comply with local, regional, and national regulations. The product must not be allowed to enter the sewer system or surface water.